Conversational AI is pushing engagers to prioritize clear, explainable guidance as patients and clinicians delegate understanding to chatbots. OpenAI’s announcement of ChatGPT Health and Anthropic’s ...
After weeks of legal drama, Ozempic is coming Hims & Hers, a telehealth company. Novo Nordisk came to an agreement with the company to offer various doses of the GLP-1 medication for DTC customers. 1 ...
In today’s Pharmaceutical Executive Daily, Vinay Prasad exits the FDA’s Center for Biologics Evaluation and Research for the ...
Based on the clinical trial findings, Ipsen is withdrawing Tazverik across all indications, including both follicular lymphoma and epithelioid sarcoma, and is discontinuing all active tazemetostat ...
GSK will receive $300 million upfront from Alfasigma for linerixibat, plus $100 million upon anticipated FDA approval and additional regulatory and sales-based milestones with tiered double-digit ...
The second exit in under a year follows controversy around CRLs for Replimune and Capricor, including criticism that mid- and ...
In a conversation with Pharmaceutical Executive Ron Lanton, Senior Partner & Global Strategist, Lanton, Lanton & Sosa Law ...
David Rosner, principal and global life sciences customer engagement leader at Deloitte, spoke with Pharmaceutical Executive ...
FDA approved Tecvayli (teclistamab-cqyv), a Johnson & Johnson drug developed for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one of line of ...
The agency pointed to what it sees as a contradictory signal within uniQure's own dataset. Sham-controlled data from a small cohort of U.S. patients showed no treatment effect at 12 months, a finding ...
Market access strategies are evolving as more biopharma companies commercialize their own therapies, requiring closer ...
In 2004, FDA released its first botanical drug guidance to the industry. This was the first time that complex botanical drugs would be allowed through FDA’s process for pharmaceutical approval. That ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results